- Pfizer confirms it will supply an additional
40,000 PAXLOVID® (nirmatrelvir tablets and ritonavir
tablets) treatment courses to the New Zealand Government,
bringing the total to 100,000 PAXLOVID treatment courses in
New Zealand for 2022. - PAXLOVID is the first
oral treatment of its kind; it is a SARS-CoV-2 main protease
(Mpro) inhibitor (also known as SARS-CoV-2 3CL protease
inhibitor) therapy. - Data demonstrated up to
86% relative risk reduction of COVID-19-related
hospitalisation or death from any cause in adults treated
with PAXLOVID within five days of symptom onset compared to
placebo.
AUCKLAND, NEW ZEALAND, 12th
September 2022 – Pfizer announced today that it
will supply the New Zealand Government with an additional
40,000 treatment courses of PAXLOVID® (nirmatrelvir
tablets and ritonavir tablets), bringing a total of 100,000
treatment courses in 2022 for New Zealand. This follows the
initial supply agreement signed in December 2021, and
Medsafe’s provisional consent for the supply and use of
PAXLOVID in New Zealand in March 2022.
Pfizer New
Zealand Managing Director, Anne Harris, said the provision
of this additional supply was an important milestone in the
fight against COVID-19, and a testament to the continued
collaboration between Pfizer and the New Zealand Government
since the beginning of the pandemic.
“Vaccination
remains the most effective way to help prevent COVID-19.
However, we know we need to tackle the virus on many
fronts,” Ms Harris said.
“PAXLOVID provides an
important second line of defence for those most at risk and
can be an important tool in helping Kiwis to stay out of
hospital and avoid serious illness and death.
“This
additional supply means more patients will be able to access
this COVID-19 oral medicine through their healthcare
professional or pharmacy and be treated at home, reducing
the impact on hospitals,” Ms Harris said.
Pfizer New
Zealand Medical Director Dr Krishan Thiru said: “PAXLOVID
is a first-of-its-kind antiviral pill for
COVID-19.
“PAXLOVID works by slowing or
stopping a virus from replicating. This may help reduce
symptoms and the risk of significant health
complications.
“This is why it is important for
people at higher risk, to get tested for COVID-19 at the
first sign of symptoms. That way if they are COVID-19
positive, they can seek medical advice quickly and find out
what treatment may be appropriate for them”, Dr Thiru
said.
PAXLOVID is an oral medicine and should be taken
within the first five days of symptomatic infection. Data
demonstrated up to 86% relative risk reduction of
COVID-19-related hospitalisation or death from any cause in
adults treated with PAXLOVID compared to placebo in those
treated within five days of symptom onset, with no deaths in
the treatment group.
PAXLOVID has provisional consent
for the treatment of coronavirus disease 2019 (COVID-19) in
adults 18 years of age and older, who do not require
initiation of supplemental oxygen due to COVID-19 and are at
increased risk of progression to hospitalisation or
death.
People seeking more information can go to:
treatpositive.co.nz.
Pharmac’s access criteria for
COVID-19 antivirals is available at: COVID-19
antivirals: Access Criteria – Pharmac | New Zealand
Government
About PAXLOVID® (nirmatrelvir
tablets and ritonavir tablets)
PAXLOVID is a
SARS-CoV-2 main protease (Mpro) inhibitor (also known as
SARS-CoV-2 3CL protease inhibitor) therapy. It was developed
to be administered orally so that it can be prescribed early
after infection, potentially helping patients avoid severe
illness (which can lead to hospitalisation and death).
Nirmatrelvir [PF-07321332], which originated in Pfizer
laboratories, is designed to block the activity of the Mpro,
an enzyme that the coronavirus needs to replicate.
Co-administration with a low dose of ritonavir helps slow
the metabolism, or breakdown, of nirmatrelvir in order for
it to remain active in the body for longer periods of time
at higher concentrations to help combat the
virus.
Nirmatrelvir is designed to inhibit viral
replication at a stage known as proteolysis, which occurs
before viral RNA replication. In preclinical studies,
nirmatrelvir did not demonstrate evidence of mutagenic DNA
interactions.
Current variants of concern can be
resistant to treatments that work by binding to the spike
protein found on the surface of the SARS-CoV-2 virus.
PAXLOVID, however, works intracellularly by binding to the
highly conserved Mpro (3CL protease) of the SARS-CoV-2 virus
to inhibit viral replication. Nirmatrelvir has shown
consistent in vitro antiviral activity against the following
variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron
BA.1 and BA.2.
PAXLOVID is generally administered at a
dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one
100 mg tablet of ritonavir, given twice-daily for five days.
One carton contains five blister packs of
PAXLOVID, as
co-packaged nirmatrelvir tablets with ritonavir tablets,
providing all required doses for a full five-day treatment
course.
© Scoop Media



















Discussion about this post